Literature DB >> 14581553

Viral blip dynamics during highly active antiretroviral therapy.

Michele Di Mascio1, Martin Markowitz, Michael Louie, Christine Hogan, Arlene Hurley, Chris Chung, David D Ho, Alan S Perelson.   

Abstract

Although intermittent episodes of low-level viremia are often observed in well-suppressed highly active antiretroviral therapy (HAART)-treated patients, the timing and amplitude of viral blips have never been examined in detail. We analyze here the dynamics of viral blips, i.e., plasma VL measurements of >50 copies/ml, in 123 HAART-treated patients monitored for a mean of 2.6 years (range, 5 months to 5.3 years). The mean (+/- the standard deviation) blip frequency was 0.09 +/- 0.11/sample, with about one-third of patients showing no viral blips. The mean viral blip amplitude was 158 +/- 132 human immunodeficiency virus type 1 (HIV-1) RNA copies/ml. Analysis of the blip frequency and amplitude distributions suggest that two blips less than 22 days apart have a significant chance of being part of the same episode of viremia. The data are consistent with a hypothetical model in which each episode of viremia consists of a phase of VL rise, followed by two-phase exponential decay. Thus, the term "viral blip" may be a misnomer, since viral replication appears to be occurring over an extended period. Neither the frequency nor the amplitude of viral blips increases with longer periods of observation, but the frequency is inversely correlated with the CD4(+)-T-cell count at the start of therapy, suggesting that host-specific factors but not treatment fatigue are determinants of blip frequency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581553      PMCID: PMC253757          DOI: 10.1128/jvi.77.22.12165-12172.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Authors:  M Hermankova; S C Ray; C Ruff; M Powell-Davis; R Ingersoll; R T D'Aquila; T C Quinn; J D Siliciano; R F Siliciano; D Persaud
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

2.  Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Authors:  D V Havlir; R Bassett; D Levitan; P Gilbert; P Tebas; A C Collier; M S Hirsch; C Ignacio; J Condra; H F Günthard; D D Richman; J K Wong
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

3.  Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection.

Authors:  S Yerly; T V Perneger; S Vora; B Hirschel; L Perrin
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

4.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

Authors:  L Ruiz; J Martinez-Picado; J Romeu; R Paredes; M K Zayat; S Marfil; E Negredo; G Sirera; C Tural; B Clotet
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

5.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Authors:  L Ruiz; G Carcelain; J Martínez-Picado; S Frost; S Marfil; R Paredes; J Romeu; E Ferrer; K Morales-Lopetegi; B Autran; B Clotet
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

7.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

8.  Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Authors:  J W Cohen Stuart; A M Wensing; C Kovacs; M Righart; D de Jong; S Kaye; R Schuurman; C J Visser; C A Boucher
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

9.  Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Authors:  H F Günthard; S D Frost; A J Leigh-Brown; C C Ignacio; K Kee; A S Perelson; C A Spina; D V Havlir; M Hezareh; D J Looney; D D Richman; J K Wong
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.

Authors:  Philippa J Easterbrook; Natalie Ives; Anele Waters; Jane Mullen; Siobhan O'Shea; Barry Peters; Brian G Gazzard
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

View more
  33 in total

1.  Understanding HIV viral load: implications for counselling.

Authors:  Patrick O'Byrne; Paul A MacPherson
Journal:  Can J Public Health       Date:  2008 May-Jun

Review 2.  A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy.

Authors:  Kasey R Claborn; Ellen Meier; Mary Beth Miller; Thad R Leffingwell
Journal:  Psychol Health Med       Date:  2014-08-11       Impact factor: 2.423

3.  The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring.

Authors:  Haitao Chu; Stephen J Gange; Xiuhong Li; Donald R Hoover; Chenglong Liu; Joan S Chmiel; Lisa P Jacobson
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

4.  Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.

Authors:  Nicole H Tobin; Gerald H Learn; Sarah E Holte; Yang Wang; Ann J Melvin; Jennifer L McKernan; Diane M Pawluk; Kathleen M Mohan; Paul F Lewis; James I Mullins; Lisa M Frenkel
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study.

Authors:  Jorge Del Romero; Jesús Castilla; Victoria Hernando; Carmen Rodríguez; Soledad García
Journal:  BMJ       Date:  2010-05-14

6.  Increased inflammation in sanctuary sites may explain viral blips in HIV infection.

Authors:  E Fabian Cardozo; Michael J Piovoso; Ryan Zurakowski
Journal:  IET Syst Biol       Date:  2016-08       Impact factor: 1.615

7.  Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Martin Tolstrup; Ole S Søgaard; Thomas A Rasmussen; Brandon F Keele; Miles P Davenport
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

8.  Modelling HIV immune response and validation with clinical data.

Authors:  H T Banks; M Davidian; Shuhua Hu; Grace M Kepler; E S Rosenberg
Journal:  J Biol Dyn       Date:  2008-10       Impact factor: 2.179

9.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.